STOCK TITAN

Horizon Therapeutics Plc - HZNP STOCK NEWS

Welcome to our dedicated page for Horizon Therapeutics Plc news (Ticker: HZNP), a resource for investors and traders seeking the latest updates and insights on Horizon Therapeutics Plc stock.

Horizon Therapeutics plc (NASDAQ: HZNP) is a global biotechnology company dedicated to the discovery, development, and commercialization of medicines for rare, autoimmune, and severe inflammatory diseases. Horizon’s mission is to blend science and compassion to transform the lives of patients who are often underserved. The company’s therapeutic portfolio includes innovative products such as TEPEZZA® (teprotumumab-trbw) and KRYSTEXXA® (pegloticase injection), which address critical medical needs.

Horizon is driven by a deep understanding of the patient journey and aims to bring clinically meaningful therapies to those who need them most. The company is heavily invested in scientific research and development, and this commitment is evident in its robust pipeline of medicines designed to address complex medical conditions.

Recently, Horizon entered into a consent order agreement with the Federal Trade Commission (FTC) to resolve a pending administrative lawsuit, clearing the way for its acquisition by Amgen (NASDAQ: AMGN). This deal is expected to close in early fourth-quarter 2023, pending final approvals. Amgen, a pioneer in biotechnology, is committed to advancing human therapeutics and has been recognized as one of “America’s Greatest Workplaces” by Newsweek and one of “America’s Climate Leaders” by USA Today.

Horizon’s commitment to combining scientific expertise with compassionate care sets it apart in the biotech industry. By focusing on areas of high unmet medical need, Horizon aims to deliver breakthrough therapies that can improve health outcomes and dramatically enhance the quality of life for patients around the world.

For more information on Horizon and its groundbreaking work, visit its official website at HorizonTherapeutics.com and follow the company on social media platforms such as Twitter, LinkedIn, Instagram, and Facebook.

Rhea-AI Summary
Horizon Therapeutics acquired by Pillartree Limited, a wholly owned subsidiary of Amgen Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Horizon Therapeutics announces court sanctioning of scheme of arrangement for acquisition by Pillartree Limited
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
none
-
Rhea-AI Summary
Horizon Therapeutics plc (NASDAQ: HZNP) receives disclosure regarding dealings with relevant securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
none
-
Rhea-AI Summary
Michael Grey discloses interests in Horizon Therapeutics plc with 0.086% ownership of ordinary shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Horizon Therapeutics plc presents new data on TEPEZZA treatment regimen and impact of TED on QOL at ATA 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Jeff Himawan discloses ownership of 0.061% of Horizon Therapeutics plc's ordinary shares. No other relevant disclosures made.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
none
-
Rhea-AI Summary
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
none
-
Rhea-AI Summary
Q32 Bio and Horizon Therapeutics have initiated a Phase 2 study to evaluate bempikibart in adult patients with severe alopecia areata, a common autoimmune disorder characterized by hair loss. The study aims to address the significant unmet medical need in this population. Bempikibart, a fully human anti-IL-7Rα antibody, has the potential to provide long-term improvement in hair loss. This development showcases the potential of bempikibart in treating autoimmune and inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
Rhea-AI Summary
Horizon confirms its issued ordinary share capital and outstanding options as of September 5, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
none

FAQ

What is Horizon Therapeutics?

Horizon Therapeutics is a global biotechnology company focused on developing medicines for rare, autoimmune, and severe inflammatory diseases.

What products does Horizon Therapeutics offer?

Horizon offers innovative products like TEPEZZA® and KRYSTEXXA®, aimed at addressing critical medical needs.

What recent achievements has Horizon Therapeutics made?

Horizon has entered into a consent order agreement with the FTC, paving the way for its acquisition by Amgen, expected to close in early fourth-quarter 2023.

Who is acquiring Horizon Therapeutics?

Amgen, a leading biotechnology company, is set to acquire Horizon Therapeutics.

How is Horizon Therapeutics contributing to medical science?

Horizon is dedicated to developing clinically meaningful therapies for rare, autoimmune, and severe inflammatory diseases, leveraging scientific research and patient-focused care.

What is the mission of Horizon Therapeutics?

Horizon aims to transform lives by delivering innovative medicines and combining science with compassion to meet unmet medical needs.

How can I learn more about Horizon Therapeutics?

Visit Horizon's official website at HorizonTherapeutics.com for more information, or follow them on social media platforms like Twitter, LinkedIn, Instagram, and Facebook.

What is the significance of Horizon’s recent agreement with the FTC?

The agreement with the FTC resolves a pending administrative lawsuit, allowing Horizon's acquisition by Amgen to proceed.

Where is Horizon Therapeutics headquartered?

Horizon Therapeutics is headquartered in Dublin, Ireland, but operates globally.

What is the focus of Horizon's research and development efforts?

Horizon focuses on developing treatments for rare, autoimmune, and severe inflammatory diseases, aiming to meet high unmet medical needs.

Horizon Therapeutics Plc

Nasdaq:HZNP

HZNP Rankings

HZNP Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link